Suven Life Science will be presenting several exciting new results and data presentations from its portfolio of investigational neuroscience new chemical entities (NCEs) at Alzheimer's Association International Conference (AAIC) being held in Boston, USA during July 13-18, 2013.
AAIC is the world’s largest conference of its kind, bringing together researchers from around the world to report and discuss groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer’s disease and related disorders.
The company has excellent portfolio of new molecules through four mechanisms of action using 5-HT6, 5-HT4, and H3 and Neuronal Nicotinic acetylcholine receptors for the treatment of cognitive impairment in Alzheimer’s disease symptomatically but also possibly useful in reducing the disease progression.
